Jiangsu Hualv Biological Technology Co.Ltd. Total Liabilities
Jiangsu Hualv Biological Technology Co.Ltd. total liabilities. Based on the latest financial reports, Jiangsu Hualv Biological Technology Co.Ltd. (300970) has total liabilities worth CN¥919.95 Million CNY (≈ $134.62 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Jiangsu Hualv Biological Technology Co.L's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Jiangsu Hualv Biological Technology Co.Ltd. (2019–2025)
Total liabilities of Jiangsu Hualv Biological Technology Co.Ltd. from 2019 to 2025. This chart illustrates how Jiangsu Hualv Biological Technology Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data.
Jiangsu Hualv Biological Technology Co.Ltd. Competitors by Total Liabilities
The table below lists competitors of Jiangsu Hualv Biological Technology Co.Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Galaxy Far East
TWO:6227
|
Taiwan | NT$7.47 Billion |
|
Element 29 Resources Inc
V:ECU
|
Canada | CA$1.25 Million |
|
SOLiD Inc
KQ:050890
|
Korea | ₩183.33 Billion |
|
Osung Advanced Materials Co. Ltd
KQ:052420
|
Korea | ₩102.26 Billion |
|
Hydratec Industries NV
AS:HYDRA
|
Netherlands | €110.20 Million |
|
Pengana Private Equity Trust
AU:PE1
|
Australia | AU$15.18 Million |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $54.27 Million |
|
Instone Real Estate Group AG
XETRA:INS
|
Germany | €1.17 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Jiangsu Hualv Biological Technology Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Jiangsu Hualv Biological Technology Co.L's balance sheet.
Liquidity & Leverage Metrics
Jiangsu Hualv Biological Technology Co.Ltd. Total Liabilities Ratios Explained
Jiangsu Hualv Biological Technology Co.Ltd. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Hualv Biological Technology Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Hualv Biological Technology Co.Ltd. (2019–2025)
The table below shows the annual total liabilities of Jiangsu Hualv Biological Technology Co.Ltd. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥797.40 Million ≈ $116.68 Million |
+1.43% |
| 2024-12-31 | CN¥786.12 Million ≈ $115.03 Million |
+42.66% |
| 2023-12-31 | CN¥551.03 Million ≈ $80.63 Million |
+20.36% |
| 2022-12-31 | CN¥457.83 Million ≈ $66.99 Million |
+4.31% |
| 2021-12-31 | CN¥438.92 Million ≈ $64.23 Million |
+39.93% |
| 2020-12-31 | CN¥313.67 Million ≈ $45.90 Million |
+11.82% |
| 2019-12-31 | CN¥280.52 Million ≈ $41.05 Million |
-- |
About Jiangsu Hualv Biological Technology Co.Ltd.
Jiangsu Chinagreen Biological Technology Group Co.,Ltd. engages in the research, development, factory cultivation, and sale of edible fungi in China. It offers Flammulina velutipes; Pleurotus eryngii, including white jade mushroom and oyster mushroom; and Maitake mushrooms. The company was founded in 2010 and is headquartered in Suqian, China.